Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 142
- Locations
- 1
- Primary Endpoint
- Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis
Study Overview
Brief Summary
The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 8 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
- •Patients who gave written informed consent were referred for MRI.
- •Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).
Exclusion Criteria
- •Pregnancy, general contraindications to MRI.
Outcomes
Primary Outcomes
Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis
Time Frame: Within 30 days prior to start of chemotherapy
MRI-positive lesions that cannot be confirmed by bone marrow cytology and pathology will be confirmed by MRI follow-up.
Secondary Outcomes
- Agreement Between MRI and 18F-FDG PET/CT at Diagnosis(Within 30 days prior to start of chemotherapy)
Investigators
Chengcheng Liao
Principal Investigator
Guangxi Medical University